Morais-Almeida Mário, Aguiar Rita, Martin Bryan, Ansotegui Ignacio J, Ebisawa Motohiro, Arruda L Karla, Caminati Marco, Canonica Giorgio Walter, Carr Tara, Chupp Geoffrey, Corren Jonathan, Dávila Ignacio, Park Hae-Sim, Hanania Nicola A, Rosenwasser Lanny, Sánchez-Borges Mario, Virchow J Christian, Yáñez Anahí, Bernstein Jonathan A, Caraballo Luis, Chang Yoon-Seok, Chikhladze Manana, Fiocchi Alessandro, González-Diaz Sandra N, Tanno Luciana Kase, Levin Michael, Ortega-Martell Jose António, Passalacqua Giovanni, Peden David B, Rouadi Philip W, Sublett James L, Wong Gary W K, Bleecker Eugene R
Allergy Centre, CUF Descobertas Hospital, Lisbon, Portugal.
The Ohio State University, Columbus, OH, USA.
World Allergy Organ J. 2020 May 16;13(5):100126. doi: 10.1016/j.waojou.2020.100126. eCollection 2020 May.
Managing patients with severe asthma during the coronavirus pandemic and COVID-19 is a challenge. Authorities and physicians are still learning how COVID-19 affects people with underlying diseases, and severe asthma is not an exception. Unless relevant data emerge that change our understanding of the relative safety of medications indicated in patients with asthma during this pandemic, clinicians must follow the recommendations of current evidence-based guidelines for preventing loss of control and exacerbations. Also, with the absence of data that would indicate any potential harm, current advice is to continue the administration of biological therapies during the COVID-19 pandemic in patients with asthma for whom such therapies are clearly indicated and have been effective. For patients with severe asthma infected by SARS-CoV-2, the decision to maintain or postpone biological therapy until the patient recovers should be a case-by-case based decision supported by a multidisciplinary team. A registry of cases of COVID-19 in patients with severe asthma, including those treated with biologics, will help to address a clinical challenge in which we have more questions than answers.
在冠状病毒大流行和 COVID-19 期间管理重度哮喘患者是一项挑战。当局和医生仍在了解 COVID-19 如何影响患有基础疾病的人群，重度哮喘也不例外。除非出现相关数据改变我们对大流行期间哮喘患者所用药物相对安全性的理解，否则临床医生必须遵循当前基于证据的指南建议，以防止病情失控和加重。此外，由于缺乏表明任何潜在危害的数据，目前的建议是，在 COVID-19 大流行期间，对于明确适用且已证明有效的生物疗法的哮喘患者，应继续给予此类治疗。对于感染了 SARS-CoV-2 的重度哮喘患者，维持或推迟生物疗法直至患者康复的决定应基于多学科团队支持的个案决定。建立一个针对重度哮喘患者（包括接受生物制剂治疗的患者）的 COVID-19 病例登记册，将有助于应对一个临床挑战，即在此挑战中我们面临的问题比答案更多。
